Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes
Open Access
- 1 June 2007
- journal article
- review article
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (6), 1335-1343
- https://doi.org/10.2337/dc07-0228
Abstract
No abstract availableThis publication has 78 references indexed in Scilit:
- CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantationBlood, 2006
- Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26Blood, 2006
- Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteersClinical Therapeutics, 2006
- Dipeptidyl peptidase IV and related enzymes in cell biology and liver disordersClinical Science, 2005
- Regulation of p38 Phosphorylation and Topoisomerase IIα Expression in the B-Cell Lymphoma Line Jiyoye by CD26/Dipeptidyl Peptidase IV Is Associated with EnhancedIn vitroandIn vivoSensitivity to DoxorubicinCancer Research, 2005
- Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IVCritical Reviews in Clinical Laboratory Sciences, 2003
- Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosaThe FASEB Journal, 2002
- In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in HumansJournal of Clinical Endocrinology & Metabolism, 2000
- Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) geneImmunogenetics, 1994
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumJBIC Journal of Biological Inorganic Chemistry, 1993